TransMedics Group (NASDAQ:TMDX) Earns "Overweight" Rating from Piper Sandler

TransMedics Group (NASDAQ:TMDX - Get Free Report)'s stock had its "overweight" rating reiterated by equities researchers at Piper Sandler in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $105.00 price objective on the stock, up from their previous price objective of $90.00. Piper Sandler's price target would suggest a potential upside of 16.69% from the company's previous close.

Several other research firms have also commented on TMDX. Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a research report on Wednesday, April 23rd. Canaccord Genuity Group restated a "buy" rating and issued a $104.00 price target on shares of TransMedics Group in a report on Tuesday, March 11th. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $124.20.

TransMedics Group Stock Down 0.5 %

Shares of TMDX traded down $0.47 during mid-day trading on Tuesday, hitting $89.98. The company's stock had a trading volume of 682,568 shares, compared to its average volume of 1,330,081. The firm has a market capitalization of $3.04 billion, a price-to-earnings ratio of 95.72 and a beta of 2.14. The company's 50-day moving average is $76.02 and its 200-day moving average is $76.72. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. TransMedics Group has a 52-week low of $55.00 and a 52-week high of $177.37.

Hedge Funds Weigh In On TransMedics Group

Several hedge funds have recently made changes to their positions in TMDX. CWM LLC grew its stake in TransMedics Group by 20.1% during the 1st quarter. CWM LLC now owns 925 shares of the company's stock valued at $62,000 after purchasing an additional 155 shares during the last quarter. Campbell Newman Asset Management Inc. boosted its position in TransMedics Group by 1.4% in the first quarter. Campbell Newman Asset Management Inc. now owns 11,619 shares of the company's stock valued at $782,000 after buying an additional 166 shares during the last quarter. Arizona State Retirement System increased its holdings in TransMedics Group by 1.9% in the 4th quarter. Arizona State Retirement System now owns 9,668 shares of the company's stock worth $603,000 after buying an additional 184 shares during the period. Hager Investment Management Services LLC lifted its stake in TransMedics Group by 38.3% during the 1st quarter. Hager Investment Management Services LLC now owns 740 shares of the company's stock valued at $50,000 after acquiring an additional 205 shares during the period. Finally, Nisa Investment Advisors LLC boosted its holdings in shares of TransMedics Group by 1.6% in the 1st quarter. Nisa Investment Advisors LLC now owns 15,824 shares of the company's stock valued at $1,065,000 after acquiring an additional 256 shares during the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.